{
  "id": 15568880,
  "title": "Nouscom raises $135M in Series D for lead cancer vaccine",
  "url": "https://urgent.news/2026/10/19/nouscom-raises-135m-in-series-d-for-lead-cancer-vaccine",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-19T06:00:32.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/nouscom-raises-135m-in-series-d-round-for-lead-cancer-vaccine/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Clinical-stage cancer biotech Nouscom has raised $135 million in an oversubscribed Series D funding round to take its lead vaccine through to a Phase 2 study. “We're super excited because there is the potential of ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "EU-Startups",
        "title": "Switzerland’s Nouscom bags €120 million to bring innovative cancer immunotherapy closer to clinical trials",
        "url": "https://urgent.news/2026/10/19/switzerlands-nouscom-bags-120-million-to-bring-innovative-cancer",
        "published": "2026-10-19T08:52:38.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}